专题：Multiple Myeloma Research and Treatments

This cluster of papers focuses on the diagnosis, staging, treatment, and molecular classification of multiple myeloma. It covers topics such as the International Myeloma Working Group criteria, novel therapies including proteasome inhibitors and immunomodulatory drugs, autologous transplantation, genomic abnormalities, and the role of the bone marrow microenvironment in disease progression.
最新文献
Discovery of Potent HDAC6-Selective Inhibitors Based on Artemisinin: Design, Synthesis, and Antitumor Evaluation

article Full Text OpenAlex

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

article Full Text OpenAlex

PCMT1 generates the C-terminal cyclic imide degron on CRBN substrates

article Full Text OpenAlex

Elevated Allele Frequency and Male-Predominance of a Common LAG3 Germline Variant in Multiple Myeloma

article Full Text OpenAlex

CO108 Evaluating the Impact of Censoring on Progression-Free Survival Comparisons of BCMA-Targeting Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

article Full Text OpenAlex

BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape

article Full Text OpenAlex

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

article Full Text OpenAlex

Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan

article Full Text OpenAlex

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

article Full Text OpenAlex

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure

article Full Text OpenAlex

近5年高被引文献
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

article Full Text OpenAlex 2746 FWCI418.2692

Teclistamab in Relapsed or Refractory Multiple Myeloma

article Full Text OpenAlex 1010 FWCI151.7188

Diagnosis and Management of Multiple Myeloma

review Full Text OpenAlex 914 FWCI138.7281

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

article Full Text OpenAlex 795 FWCI116.123

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

article Full Text OpenAlex 642 FWCI187.5419

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

article Full Text OpenAlex 640 FWCI187.8363

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

article Full Text OpenAlex 590 FWCI87.8914

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

article Full Text OpenAlex 588 FWCI57.3573

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

article Full Text OpenAlex 502 FWCI147.7959

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

article Full Text OpenAlex 460 FWCI135.1361